Citigroup has downgraded QuidelOrtho Corp (QDEL) to Neutral from Buy, effective October 6, 2025. The stock currently trades at $24.25.
This downgrade suggests increased caution regarding QuidelOrtho's outlook, potentially reflecting concerns about competitive pressures, market conditions, or execution risks that may affect the company's performance.
QuidelOrtho operates as a vitro diagnostics company specializing in immunoassay and molecular testing, clinical chemistry, and transfusion medicine. The company, headquartered in San Diego, California, employs approximately 6,600 people. Its diverse product offerings span various business units, including labs, molecular diagnostics, point of care, and transfusion medicine.
As of November 1, 2025, the analyst consensus for QuidelOrtho includes 3 Strong Buy, 5 Buy, 5 Hold, and 1 Sell ratings, indicating a general Buy sentiment among analysts. Recent earnings performance has shown notable surprises, with Q3 2025 reporting an EPS of $0.80 against an estimate of $0.47, marking a 70.7% surprise.
Upcoming earnings are projected for August 3, 2026, with an estimated EPS of $0.22 and revenue of $645.3 million. Such decisions reflect the dynamic nature of analyst ratings, which can change as new information becomes available. Investors should consider multiple factors, including company fundamentals and market conditions, when interpreting these ratings.